CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted EBT Margin of 4267.12% for Q1 2026, up 91.99% on a QoQ basis from 53305.0% in Q4 2025, and down 418693.0% year-over-year from N/an in Q1 2025.
CollPlant Biotechnologies (CLGN) EBT Margin (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies' EBT Margin history runs 10 years deep, the most recent figure standing at 4267.12% for Q1 2026.
- Quarterly EBT Margin fell 418693.0% year-over-year to 4267.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9107.2% (down 795327.0% YoY) and the FY2025 annual result came in at 1684.35%, up 594283.0% from the prior year.
- EBT Margin was 4267.12% for Q1 2026 at CollPlant Biotechnologies, up from 53305.0% in the prior quarter.
- Across five years, EBT Margin topped out at 4417.35% in Q1 2024 and bottomed at 113550.0% in Q3 2024.
- A 5-year average of 15537.94% and a median of 4183.1% in 2026 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin slumped 11354999 bps — and 2025, when it jumped 10899545 bps.
- CollPlant Biotechnologies' EBT Margin stood at 46796.55% in 2022, then soared by 83 bps to 8138.8% in 2023, then tumbled by 100 bps to 16305.49% in 2024, then slumped by 227 bps to 53305.0% in 2025, then soared by 92 bps to 4267.12% in 2026.
- Business Quant data shows CLGN's EBT Margin at 4267.12% in Q1 2026, 53305.0% in Q4 2025, and 4554.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 34.77% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 18.99% |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | -4,267.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -53,305.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -16,305.49% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -8,138.80% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -46,796.55% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -73,416.77% |
| Sep 30, 2021 | 51,361.43% |
| Jun 30, 2021 | -431.69% |
| Mar 31, 2021 | 69.62% |